SCHEMBL16769749

SCHEMBL16769749

CC(=O)C1CCN(c2ccc(OC3CCC3)nc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ACACB O00763 14/20 0.57
LCAT P04180 1/20 0.46
HRH3 Q9Y5N1 4/20 0.41
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16648540 0.85 MAPT (0.53) ACACB
SCHEMBL16769739 0.84 CHRNB2 (0.54) ACACBLCAT
SCHEMBL16769746 0.81 ACACB (0.56) ACACBLCATHRH3
SCHEMBL16769744 0.80 LCAT (0.47) ACACBLCATHRH3
SCHEMBL16695268 0.80 NOTUM (0.55) ACACB
SCHEMBL3333248 0.79 ACACB (0.48) ACACBLCATHRH3NAMPT
SCHEMBL16695251 0.79 ACACB (0.48) ACACBHRH3
SCHEMBL16695276 0.79 ACACB (0.48) ACACBHRH3
SCHEMBL20000628 0.78 ACACB (0.47) ACACBLCATHRH3NAMPT
SCHEMBL3104288 0.75 GPR119 (0.57) ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE LCAT, LPL, LCLAT1 ACACB 209/4885LCAT 1/4885HRH3 3681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.